AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAEON
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAeon Biopharma Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 09, 2021
āļāļĩāļāļĩāđāļBancroft (Robert E)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ5
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 09
āļāļĩāđāļāļĒāļđāđ5 Park Plaza
āđāļĄāļ·āļāļIRVINE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX â NASDAQ Basic Amex
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92614
āđāļāļĢāļĻāļąāļāļāđ19493546499
āđāļ§āđāļāđāļāļāđhttps://aeonbiopharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAEON
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 09, 2021
āļāļĩāļāļĩāđāļBancroft (Robert E)
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Dr. Chad Oh, M.D.
Chief Medical Officer
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Ms. Shelley Thune
Independent Director
Mr. Seongsoo Park
Director
Ms. Jennifer Sy
Chief Accounting Officer
Mr. Robert Bancroft
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Dr. Chad Oh, M.D.
Chief Medical Officer
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director